Telix Pharmaceuticals Acquires ARTMS Inc.

Telix Pharmaceuticals to Acquire ITM Isotope Technologies Munich

September 21, 2026

Pharmaceuticals

Telix Pharmaceuticals signed an agreement to acquire 100% of ITM Isotope Technologies Munich for $1.65 billion upfront, plus up to $700 million in contingent payments tied primarily to regulatory approvals and sales milestones for ITM-11. The deal combines Telix’s radiopharmaceutical development and commercial platform with ITM’s isotope manufacturing, distribution network, and therapeutic pipeline; it remains subject to shareholder and regulatory approvals.

CQ Medical Acquires Bionix Radiation Therapy Business Unit

December 1, 2025

Medical Devices

CQ Medical has acquired the Radiation Therapy business unit from Bionix, expanding CQ Medical’s patient positioning and radiotherapy marking product portfolio. The deal transfers Bionix’s radiation therapy product lines and commercial team to CQ Medical while Bionix retains its Ambulatory Care business based in Maumee, Ohio.

LIXTE Biotechnology Acquires Liora Technologies Europe Ltd

November 25, 2025

Medical Devices

LIXTE Biotechnology Holdings, Inc. (Nasdaq: LIXT) has completed the acquisition of Liora Technologies Europe Ltd., a UK-based developer of the LiGHT proton therapy system. The deal brings Liora's proprietary LiGHT System and Daresbury-based operations into LIXTE as a wholly owned subsidiary to expand the company's capabilities into radiotherapy and pursue joint treatment-center revenue models.

Telix Pharmaceuticals to Acquire RLS (USA) to Expand North American Radiopharmacy Manufacturing and Distribution

September 22, 2024

Healthcare Services

Telix Pharmaceuticals Limited has agreed to acquire RLS (USA) Inc. from its parent company, RLS Group Ltd., to expand Telix’s North American radiopharmaceutical manufacturing and distribution platform. The deal leverages RLS’s 31 Joint Commission-accredited radiopharmacies to build a radiometal production and distribution network and improve capacity for PET, SPECT, and therapeutic isotopes.

Telix Pharmaceuticals Acquires QSAM Biosciences

February 8, 2024

Biotechnology

Telix Pharmaceuticals Limited has entered into an agreement to acquire QSAM Biosciences, Inc., adding QSAM's lead radiopharmaceutical candidate 153Sm-DOTMP (Samarium-153-DOTMP) to Telix's therapeutic pipeline. The asset expands Telix's oncology focus into bone-targeting radiopharmaceuticals with potential applications in pain management of bone metastases and osteosarcoma (including pediatric indications).

Temasek-Led €255M Investment Round in ITM Isotope Technologies Munich SE

June 5, 2023

Biotechnology

Temasek led a €255 million equity investment round in ITM Isotope Technologies Munich SE, with participation from QIA, BlackRock Alternatives, Nextech, ATHOS and Carbyne. The proceeds (mostly primary capital with a minority secondary component) will advance ITM's targeted radionuclide therapy pipeline, support late-stage clinical development of ITM-11, and expand GMP manufacturing capacity for n.c.a. 177Lu and 225Ac while bolstering commercial infrastructure.